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Tumor-induced senescent T cells promote the secretion
of pro-inflammatory cytokines and angiogenic factors
by human monocytes/macrophages through a
mechanism that involves Tim-3 and CD40L
MC Ramello1, J Tosello Boari1, FP Canale1, HA Mena2, S Negrotto2, B Gastman3, A Gruppi1, EV Acosta Rodríguez1 and CL Montes*,1
Solid tumors are infiltrated by immune cells where macrophages and senescent T cells are highly represented. Within the tumor
microenvironment, a cross-talk between the infiltrating cells may occur conditioning the characteristic of the in situ immune
response. Our previous work showed that tumors induce senescence of T cells, which are powerful suppressors of lympho-
proliferation. In this study, we report that Tumor-Induced Senescent (TIS)-T cells may also modulate monocyte activation. To gain
insight into this interaction, CD4+ or CD8+TIS-T or control-T cells were co-incubated with autologous monocytes under
inflammatory conditions. After co-culture with CD4+ or CD8+TIS-T cells, CD14+ monocytes/macrophages (Mo/Ma) exhibit a higher
expression of CD16+ cells and a reduced expression of CD206. These Mo/Ma produce nitric oxide and reactive oxygen species;
however, TIS-T cells do not modify phagocyte capacity of Mo/Ma. TIS-T modulated-Mo/Ma show a higher production of pro-
inflammatory cytokines (TNF, IL-1β and IL-6) and angiogenic factors (MMP-9, VEGF-A and IL-8) and a lower IL-10 and IP-10
secretion than monocytes co-cultured with controls. The mediator(s) present in the supernatant of TIS-T cell/monocyte-
macrophage co-cultures promote(s) tubulogenesis and tumor-cell survival. Monocyte-modulation induced by TIS-T cells requires
cell-to-cell contact. Although CD4+ shows different behavior from CD8+TIS-T cells, blocking mAbs against T-cell immunoglobulin
and mucin protein 3 and CD40 ligand reduce pro-inflammatory cytokines and angiogenic factors production, indicating that these
molecules are involved in monocyte/macrophage modulation by TIS-T cells. Our results revealed a novel role for TIS-T cells in
human monocyte/macrophage modulation, which may have deleterious consequences for tumor progression. This modulation
should be considered to best tailor the immunotherapy against cancer.
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Clinical and experimental studies have established that
several types of solid tumors are characterized by infiltration
of both innate and adaptive immune cells. Indeed, it has been
reported that tumors can be infiltrated by different cell
populations such as B cells, NK cells, Th1 and Th2 cells,
regulatory T cells (Tregs), senescent T cells and macro-
phages, among others.1–3 Investigating the nature and
effector function of these tumor-infiltrating subsets is highly
relevant as accumulating evidence indicates that a dynamic
cross-talk between tumors and immune system cells can
regulate tumor growth and metastasis.4,5
Macrophages constitute a major component of the leuko-
cytes that infiltrate tumors. Tumor-associated macrophages
(TAMs) derive almost entirely from circulating monocytes,
which acquire distinct phenotypic characteristics and diverse
functions according to the tumor microenvironment. Proto-
typically, two different types of activated macrophages have
been recognized: the classically activated (M1) or pro-
inflammatory macrophages and the alternatively activated
(M2) macrophages. Thus, in response to diverse signals like
cytokines or membrane receptor ligation, macrophages
undergo M1 or M2 polarization states characterized by
particular profiles of cytokine and chemokine production. M1
macrophages express high levels of pro-inflammatory cyto-
kines, major histocompatibility complex (MHC) molecules and
inducible nitric oxide (NO) sintetase. By contrast, M2 macro-
phages downregulate MHC class II and show increased
expression of the anti-inflammatory cytokine IL-10 and
mannose receptor. In addition, macrophages can also be
polarized into a M2-like state, which shares some but not all
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the signature features of M2 cells.1 Macrophages with
intermediate or overlapping phenotypes have been observed
in many pathological conditions in vivo, probably as a result of
the effect of diverse signals that occur along different times of
the immune response. In fact, many studies emphasize the
heterogeneity and plasticity of macrophages and indicate that
typical M1 and M2 phenotypes are extremes of a wide
spectrum of functional states.6–8
Within the tumor microenvironment, the macrophages
interact with or receive signals from different tumor-
infiltrating immune cells such as Tregs, myeloid-derived
suppressor cells, Th1 and Th2 cells, among others.1,9 This
interaction may regulate the profile of macrophage activation
and consequently impact on tumor progression. It has been
described that the excessive activity of either M1 or M2
subsets may be detrimental to the host by preventing the
development of an efficient anti-tumor immune response.10
Understanding the cellular interactions that lead to the control
of monocyte/macrophage (Mo/Ma) activation is, therefore, of
fundamental importance to the field of tumor immunology.
Senescent T cells are reported to be increased during
chronic infections and some tumor processes.11,12 In fact,
senescent T cells circulate in the peripheral blood of most
cancer patients and infiltrate tumors.2 Although the hallmark of
human senescent T cells is the loss of CD27 and CD28
expression, other features of these cells include shortened
telomeres, reduced proliferative capacity and cytokine pro-
duction as well as suppressor activity.13,14 We previously
reported that, after a brief contact with tumor cells, CD4+ as
well as CD8+ T lymphocytes from healthy donors acquire a
senescent phenotype. These CD4+ and CD8+ tumor-induced
senescent (TIS)-T cells are characterized by the loss of CD27
and CD28 expression, lack of proliferative capacity, telomere
shortening and increment in the expression of senescence-
associated molecules such as p53, p21 and p16. Remarkably,
these CD4+ and CD8+ TIS-T populations also show a potent
suppressive ability.15 We also demonstrated that tumor-
induced senescence of T cells is triggered by soluble factors
secreted by tumor cells and that this process can be prevented
by IL-7.16 These data support the hypothesis that, within the
tumor microenvironment, tumor-infiltrating T lymphocytes
encounter tumor cells that promote their senescence and
dysfunction. These TIS-T cells would be able to suppress the
lympho-proliferative response and potentially modulate other
immune cells. Thus, they may serve as an intercellular cross-
talk in the tumor microenvironment and impact on tumor
progression.
Although macrophages and TIS-T lymphocytes are both
highly represented in tumors, the biological consequences of
a TIS-T cell and macrophage interaction have not been
studied so far. Here, we demonstrate that monocytes co-
cultured with TIS-T cells in inflammatory conditions increase
their production of inflammatory cytokines and angiogenic
factors. In addition, we determined that Mo/Ma modulation
mediated by TIS-T lymphocytes requires cell-to-cell contact
and identified T-cell immunoglobulin and mucin protein 3
(Tim-3) and CD40 ligand (CD40L) molecules as mediators of
this previously uncharacterized modulatory function of
senescent T cells.
Results
TIS-T lymphocytes induce classical activation in Mo/
Ma. To study whether CD4+ or CD8+ TIS-T lymphocytes can
steer the differentiation of human monocytes, CD14+ mono-
cytes were cultured alone or with autologous CD4+ or CD8+
TIS-T lymphocytes or control CD4+ or CD8+ T lymphocytes
stimulated with anti-CD3 mAb. After 40 h of culture, pheno-
type markers were evaluated by flow cytometry on CD14+
cells. We first analyzed the expression of CD16, typically
associated with pro-inflammatory or classically activated
monocytes. As determined by the higher mean of fluores-
cence intensity (MFI), we found a significantly increased
expression of CD16 on Mo/Ma co-cultured with CD4+ or CD8+
TIS-T cells than on those co-cultured with control counter-
parts (Figure 1a). These control co-cultures (CCs) exhibited
similar expression of CD16 than Mo/Ma cultured alone
(Figure 1a). In addition, we observed a reduced expression
of CD206, an alternative activation marker, in Mo/Ma cultured
with CD4+ or CD8+ TIS-T lymphocytes compared to Mo/Ma
cultured alone or with CD4+ or CD8+ control-T lymphocytes
(Figure 1b). In contrast, no differences were detected in the
expression of HLA-DR and co-stimulatory molecules such as
CD86 and B7.H4 (data not shown). To further evaluate the
features of the Mo/Ma cultured with TIS-T cells, we studied
phagocytic activity, shown to be increased in alternatively
activated human macrophages.1 In line with their phenotype
of classically activated cells, Mo/Ma co-incubated with CD4+
or CD8+ TIS-T lymphocytes did not modify their phagocyte
capacity (Figure 1c).
To establish whether the acquisition of a classically
activated phenotype is accompanied by the corresponding
effector function, we evaluated Mo/Ma ability to produce
reactive nitrogen and oxygen species. The percentages of NO
and Reactive Oxygen Species (ROS)-producing CD14+ cells,
were higher in cultures of Mo/Ma with CD4+ or CD8+ TIS-T
lymphocytes compared with those with control CD4+ or CD8+
T cells (Figure 1d, P=0.011 and P= 0.014, respectively, and
Figure 1e, P=0.041 and P=0.006, respectively). Besides the
percentages of producing cells, the analysis of the MFI
showed that Mo/Ma cultured with TIS and control-T cell
increased NO and ROS production relative to Mo/Ma cultured
alone (Figures 1d and e). Altogether these results indicate that
both TIS and control-T cells promote ROS and NO production
by Mo/Ma, but TIS-T cells have a stronger effect.
TIS-T lymphocytes enhance the pro-inflammatory
response of Mo/Ma. Inflammatory responses have decisive
roles at different stages of tumor development, including
initiation, promotion, malignant conversion, invasion and
metastasis. Most, if not all, solid malignancies promote
inflammation through the secretion of molecules, which
activate macrophages through toll-like receptor 4 (TLR4) and
TLR2.17 Thus, considering that an inflammatory microenvir-
onment is a hallmark component of all tumors, we sought to
determine whether CD4+ or CD8+ TIS-T lymphocytes can
modulate the effector function of Mo/Ma triggered by a
powerful pro-inflammatory stimulus such as LPS. Compared
with those cultured alone or with control-T lymphocytes, LPS-
stimulated Mo/Ma co-cultured with CD4+ or CD8+ TIS-T cells
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produced increased amounts of pro-inflammatory cytokines
such as IL-1β, IL-6 and TNF and decreased amounts of the
anti-inflammatory cytokine IL-10. In contrast, both TIS- and
control-T cells similarly promoted IL-1Ra secretion by Mo/Ma
(Figure 2a). To exclude TIS-T cells as a potential source of
cytokines in the CC assays, we evaluated the identity of the
cytokine producing cells by flow cytometry. Remarkably,
490% of cells within the TNF-, IL-6- or IL-1β-producing
population detected in the TIS-T cells/Mo-Ma CCs were
CD14+, while CD3+ cells were only found in non-cytokine
producing population (Supplementary Figure 1a).
The enhanced pro-inflammatory cytokine response to LPS
observed in CD4+ or CD8+ TIS-T cells-modulated Mo/Ma
could not be explained by an increased CD14 nor TLR-4
expression (Supplementary Figures 2a and b) but correlated
with a greater activation of the canonical pathway of NF-κB.
Indeed, upon LPS stimulation, Mo/Ma modulated by CD4+ or
CD8+ TIS-T lymphocytes showed an increased expression
of phospho-IκBα with respect to those co-incubated CD4+ or
CD8+ control-T lymphocytes, which became even more
evident after 120 min of stimulation (Figure 2b). In concor-
dance, we detected that TIS-T-modulated Mo/Ma exhibited
higher p65 translocation (Figure 2c). In the same line of
evidence we observed that, upon LPS stimulation, Mo/Ma
co-incubated with CD4+ and CD8+ TIS-T lymphocytes
exhibited higher intracellular tyrosine phosphorylation
(Supplementary Figure 2c). The activation of the non-
canonical pathway of NF-κB was evaluated by the expression
of p100 and p52 and no differences were detected between
Mo/Ma co-incubated with TIS- or control-T lymphocytes
(Figure 2b).
TIS-T lymphocytes promote the production of angiogenic
factors and inhibit IP-10 secretion by Mo/Ma. Considering
that the activation of the canonical pathway of NF-κB has
been implicated in the induction of pro-tumorigenic
mediators,18 we determined the production of angiogenic
factors such as MMP-9, VEGF-A and IL-8 by LPS-stimulated
Figure 1 CD4+ and CD8+ TIS-T cells induce classical activation in monocytes/macrophages. Monocytes were cultured alone, with CD4+ or CD8+ control T cells, or with CD4+
or CD8+ TIS-T cells (in 1:1 ratio), in the presence of anti-CD3 mAb (2 μg/ml). The phenotype of Mo/Ma and their ability to produce NO and ROS was assessed after 40 h of co-
culture. (a) CD16 expression (average MFI± S.E.M.) on Mo/Ma co-cultured with TIS-T cells or control T cells relative to Mo/Ma cultured alone. (b) CD206 expression (average
MFI± S.E.M.) on Mo/Ma co-cultured with TIS-T cells or control T cells relative to Mo/Ma cultured alone. (c) Percentage± S.E.M. of phagocytosing CD14+ cells. *Po0.05,
**Po0.01, ***Po0.001, ns, not significant (P40.05); statistical analysis were performed by using one way ANOVA test (n= 4). Histograms represent (d) NO and (e) ROS
production by Mo/Ma co-cultured with CD4+ (upper graphs) or CD8+ (lower graphs) T cells. Percentages±S.E.M. (n= 4) of NO- and ROS-producing CD14+ cells are indicated
in the histograms. (NO: P= 0.011, CD4+ TIS-T/Mo-Ma versus CD4+ control T/Mo-Ma and P= 0.014 CD8+ TIS-T/Mo-Ma versus CD8+ control T/Mo-Ma. ROS: p= 0.041 CD4+
TIS-T/Mo-Ma versus CD4+ control T/Mo-Ma and p= 0.006 CD8+ TIS-T/Mo versus CD8+ control T/Mo-Ma). Bar graphs represent MFI of NO and ROS-CD14+ producing cells
relative to Mo/Ma cultured alone. *Po0.05, **Po0.01, ns, not significant (P40.05); statistical analysis were performed using one-way ANOVA test (n= 4)
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Figure 2 CD4+ and CD8+ TIS-T cells promote pro-inflammatory cytokines and angiogenic factors production by monocytes/macrophages. Monocytes were cultured as
described in Figure 1. (a) After 40 h of co-culture, LPS was added and 48 h later cytokine production was measured. Graphics show pro-inflammatory cytokines (IL-1β, IL-6 and
TNF) and anti-inflammatory cytokines (IL-10 and IL-1Ra) production. All results are shown as mean±S.E.M. *Po0.05, **Po0.01, ***Po0.001, ns, not significant (P40.05);
statistical analysis were performed using one-way ANOVA test. Data of seven experiments performed with different donors are shown. (b) After 40 h, co-cultures were either left
as is or LPS stimulated for 60 and 120 min. Afterward, co-cultures were depleted of T cells, and total Mo/Ma lysates were separated on SDS–PAGE gels and immunoblotted with
antibodies against the indicated proteins. Anti-p38 antibodies were used for equal loading control. The densitometric protein levels of phospho-IкBα were normalized to the
respective levels of p38 and indicated in the bar graph. (c) After 40 h, co-cultures were LPS stimulated for 120 min. Then, T cells were depleted and Mo/Ma was stained as
indicated. Confocal microscopy photographs (×60) show p65 protein (green) and nuclear (propidium iodide) (red) staining. Data are representative from three independent
experiments. (d) After 40 h of co-culture, LPS was added and 48 h later, the production of angiogenic (MMP-9, VEGF-A and IL-8) and angiostatic (IP-10) factors was measured.
Graphics show the average of angiogenic or angiostatic factor production in culture supernatant of Mo/Ma co-incubated with TIS-T cells or control T cells relative to culture
supernatant of Mo/Ma cultured alone (n= 7). Statistical analyses were performed using one-tailed paired t-test. P-values (TIS-T/Mo-Ma. co-culture versus control T/Mo-Ma co-
culture) are indicated on graphics
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Mo/Ma co-cultured with TIS-T lymphocytes. Figure 2d shows
that the normalized amounts of MMP-9 quantified in the
culture supernatants of LPS-stimulated CD4+ or CD8+ TIS-T
cell/Mo-Ma CCs (relative to Mo/Ma cultured alone) were
significantly higher than those detected in supernatants of
CD4+ or CD8+ control-T cell/Mo-Ma CCs. Similar to MMP-9,
the amounts of VEGF-A and IL-8/CXCL8 measured in culture
supernatant of LPS-stimulated CD4+ or CD8+ TIS-T cell/Mo-
Ma CCs were significantly higher than those quantified in the
culture supernatant of LPS-stimulated control-T cells/Mo-Ma
CCs. As we previously did, we excluded T cells as possible
sources of MMP-9 and IL-8 in the TIS-T lymphocyte/Mo-Ma
CCs by determining, after intracellular staining, that 490%
of the MMP-9 or IL-8 producing cells were CD14+
(Supplementary Figure 1b). In addition, we observed that
anti-CD3/anti-CD28-stimulated CD4+ or CD8+ TIS-T cells do
not produce VEGF-A (data not shown).
We next evaluated the production of IP-10/CXCL10, a factor
commonly produced by monocytes that exhibits a potent
angiostatic activity and inhibits tumorigenesis.19 In the culture
supernatant of Mo/Ma co-cultured with CD4+ and CD8+ TIS-T
lymphocytes we detected a reduced concentration of IP-10
with respect to culture supernatants of Mo/Ma cultured with
control-T cells (Figure 2d).
We next evaluated the pro-angiogenic effects of the super-
natants from TIS-T cells/Mo-Ma CCs in assays of tubulogenesis
and wound healing. The capillary-tube formation elicited by the
culture supernatants from CD4+ or CD8+ TIS-T-modulated Mo/
Ma was significantly augmented with respect to that induced by
supernatant from control cultures (Figure 3a). In addition, we
observed that wound healing of Human microvascular endo-
thelial cells (HMEC) treated with supernatants from CD4+ or
CD8+ TIS-T cell/Mo-Ma CCs exhibited a similar wound closure
than HMEC treated with supernatants of control-T cells/Mo-Ma
CCs or Mo/Ma cultured alone (data not shown).
To establish whether factors present in supernatant of TIS-T
cell/Mo-Ma CCs may have any impact on tumor cell death. We
evaluated cell death of HeLa cells treated with different culture
supernatants. We observed that after 48 h of culture, HeLa
cells incubated with supernatant of Mo/Ma co-cultured with
CD4+ or CD8+ TIS-T cells showed a reduced cell death
percentage compared with the corresponding controls
(Figure 3b). Altogether these results indicate that some
mediator/s present in the culture supernatant of TIS-T cell/
Mo-Ma CCs promote tubulogenesis and survival of tumor cells
but not wound healing. These findings are not conflictive as
the molecular mechanisms involved in tubulogenesis and
wound healing are not identical.20
Figure 3 Culture supernatants of TIS-T-modulated monocytes/macrophages promote pro-angiogenic responses. (a) HMEC-1 were seeded on plates coated with Matrigel
and cultured in EGM-2 supplemented with supernatants of TIS-T or control T cell/Mo-Ma co-cultures or supernatants of Mo/Ma cultured alone. After 18 h, tube formation was
examined and the total number of branch points was quantified on the entire surface of each well. Bar graph shows the number of branch points elicited by control Tor TIS-T/Mo-
Ma co-culture supernatants relative to culture supernatants of Mo/Ma cultured alone (n= 3). Statistical analyses were performed using one-tailed paired t-test. P-values (TIS-T/
Mo-Ma co-cultures versus control T/Mo-Ma co-cultures) are indicated on graph. (b) HeLa cells were treated with mitomycin C to inhibit cell proliferation. Then, HeLa cells were
cultured with supernatant of TIS-T or control T cell/Mo-Ma co-cultures or supernatants of Mo/Ma cultured alone. After 48 h HeLa cell death was measured by flow cytometry by
using 7-AAD labeling. In all cases, fill histograms represent unstained HeLa cells. Data are representative from three independent experiments
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TIS-T lymphocytes modulate Mo/Ma through Tim-3/
galectin-9 (Gal-9) and CD40L/CD40 pathways. To investi-
gate whether Mo/Ma modulation mediated by TIS-T lympho-
cytes requires signals derived from cell contact or soluble
factors, we performed TIS-T cell/Mo-Ma CCs as before and
also in a transwell system (TW). The disruption of physical
contact between monocytes and CD4+ or CD8+ TIS-T cells
completely abrogated the ability of TIS-T cells to potentiate
Mo/Ma production of TNF, IL-1β, IL-6 and IL-8 (Figure 4).
To further elucidate the pathways implicated in Mo/Ma
modulation by TIS-T lymphocytes, we performed a phenotypic
profiling of CD4+ and CD8+ TIS-T cells and Mo/Ma focusing
on surface molecules involved in the pro-inflammatory
cytokine induction in Mo/Ma.21–23 We observed that after
anti-CD3 stimulation, both CD4+ and CD8+ TIS-T cells
exhibited a higher expression of Tim-3 and CD40L than
stimulated CD4+ and CD8+ control-T cells (Figure 5a).
Remarkably, we determined that Mo/Ma stimulated with LPS
under our in vitro conditions expressed, on the cell surface as
well as intracellulary, Gal-9, the known ligand of Tim-324
(Figure 5b). Furthermore, 20% of the LPS-stimulated CD14+
population expressed CD40, the receptor of CD40L
(Figure 5c).
In addition, we confirmed previous observations by Zhang
et al.25 that showed that CD14+ Mo/Ma exhibited a fairly high
level of Tim-3 expression; however, it is significantly down-
regulated in the CC conditions (Figure 5d).
To test whether Tim-3/Gal-9 and CD40L/CD40 pathways
participated in the interaction among TIS-T lymphocytes and
Mo/Ma that favored production of pro-inflammatory cytokines
and angiogenic factors, monocytes and TIS-T lymphocytes
were cultured in the presence of blocking antibodies against
Tim-3 or CD40L. We observed that IL-1β, IL-6, VEGF-A and
IL-8 production by Mo/Ma co-cultured with CD4+ TIS-T was
significantly reduced after anti-Tim-3 treatment (median
reduction: 12%, 11%, 59% and 36%, respectively)
(Figure 6a). Furthermore, CCs with cells from five out of
seven donors reduced TNF secretion upon anti-Tim-3 treat-
ment. However, inclusion of the non-responding donors in the
statistical analysis ended in a non-significant difference.
Blockade of the CD40L/CD40 interaction resulted in a reduced
IL-1β, IL-6, TNFand IL-8 production in CD4+TIS-T cell/Mo-Ma
CCs (median reduction: 22%, 17%, 37%and 38%, respectively).
Again, most of the CCs from different donors (five out of six)
showed reduced amounts of VEGF-A after anti-CD40L
treatment (median reduction: 31%), though the difference
considering all donors was not statistically significant.
Mo/Ma co-cultured with CD8+ TIS-T lymphocytes showed a
slightly different response to the presence of blocking mAbs
than those co-cultured with CD4+ TIS-T cells. Thereby, we
observed that anti-Tim3 mAb was able to significantly reduce
the secretion of TNF, VEGF-A and IL-8 (median reduction: 36,
70 and 23%, respectively) but not of IL-1β and IL-6, although
most of the CCs from different donors showed a trend toward a
reduced production of these cytokines. Moreover, anti-CD40L
treatment significantly reduced the amounts of TNFand IL-8 in
these CCs (median reduction: 41% and 61%, respectively),
whereas it had no evident effect on IL-1β, IL-6 or VEGF-A
production (Figure 6b).
Figure 4 Monocytes/macrophages modulation by CD4+ and CD8+ TIS-T cells requires cell-o-cell contact. Monocytes were co-cultured with CD4+ or CD8+ TIS-T cells in the
same well (CoCulture, CC, gray bars) or cultured separately by a Transwell (TW, black bars), with stimulated CD4+ or CD8+ TIS-T cells in the insert and monocytes in the lower
well. After 40 h of co-culture, LPS was added and 48 h later TNF, IL-1β, IL-6 and IL-8 were measured. Bars represent average of cytokine/angiogenic factor production± S.E.M.
(n= 3). Statistical analyses were performed using one-tailed paired t-test. P-values (CC versus TW) are indicated on each graph
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Figure 6 TIS-T cells modulate monocytes/macrophages through Tim-3/Gal-9 and CD40L/CD40 pathways. Monocytes were cultured with CD4+ or CD8+ TIS-T cells in the
presence of blocking mAb against Tim-3 or CD40L molecules or IgG1κ isotype control. After 40 h LPS was added and 48 h later cytokines and angiogenic factors were measured.
Cytokine and angiogenic factors production in CD4+ TIS-T/Mo-Ma (a) and CD8+ TIS-T/Mo-Ma (b) co-cultures, in the presence of isotype control paired to blocking mAb.
Statistical analysis was performed by using Wilcoxon signed rank test. P-values (TIS-T/Mo-Ma co-cultures with IgG1κ isotype control versus TIS-T/Mo-Ma co-cultures with
blocking mAb) are indicated on graphs
Figure 5 Phenotypic profiling of CD4+ and CD8+ TIS-T cells and monocytes/macrophages. (a) Tim-3 and CD40L expression on stimulated control T cells and TIS-T cells.
Bars represent Tim-3 or CD40L expression (MFI±S.E.M.) (n= 6). Statistical analyses were performed using one-tailed paired t-test. P-values (TIS-T cells versus control T cells)
are indicated on graph. (b–d) Monocytes were culture 40 h and then were either unstimulated or LPS-stimulated for 18 hours. (b) Representative histograms of Gal-9 expression
on surface and intracellulary on LPS-stimulated or non-stimulated monocytes. (c) Representative histogram of CD40 expression on LPS-stimulated or non-stimulated monocytes.
(d) Representative histograms of Tim-3 expression on recently isolated human monocytes (0 h, before culture) and on LPS-stimulated or non-stimulated monocytes. In all cases,
fill histograms represent FMO control. Representative histograms are shown from one donor out of at least three different donors
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Discussion
Previously it has been demonstrated that TAMs are a
heterogeneous cell population that acquire different pheno-
types influenced by cancer cells, surrounding stroma as well
as immune system cells which infiltrate tumors.7 Interactions
between TAMs with tumor infiltrating-Tregs, B cells and Th2
cells have been previously described.1 However, the interac-
tion between senescent T cells and macrophages and their
biological relevance has not been studied so far. Our work
provides evidence for previously uncharacterized roles of
human CD4+ and CD8+ TIS-T lymphocytes in the modulation
of macrophage activity. Thus, TIS-T lymphocyte emerges as a
new relevant player in the complex interaction between tumor
and tumor-infiltrating cells that influences tumor progression.
The functional diversity of macrophages is critical to
orchestrate the variety of effector functions that range from
inflammation and phagocytosis to immunoregulation and
tissue remodeling. Particularly in the tumor microenvironment,
the phenotype and function of TAMs have important con-
sequences for tumor progression.26 Indeed, M1macrophages
are efficient immune cells able to kill tumor cells and to
promote anti-tumor responses.7 However, M1 phenotype has
also been associated with cancer initiation and promotion.27
Once the tumor is initiated and as it progresses toward
malignancy, the macrophage phenotype has been shown to
change to the M2 phenotype. Accordingly, it has been
demonstrated that TAMs are composed of distinct populations
that share features of M1 and M2 types.28,29
It has been demonstrated that T lymphocytes modulate
macrophage function in vivo and in vitro. Thus, by producing
IFNγ, Th1 cells can drive classical M1 polarization, while Th2
cells direct M2 polarization through IL-4, IL-13 and IL-33.7,30
Studies performed by Tiemessen et al.9 highlighted additional
T cell subsets able to modulate Mo/Ma function. These
authors demonstrated that human monocytes cultured in the
presence of Tregs cells differentiate into M2-like macro-
phages. Similarly, we observed that after co-incubation with
CD4+ or CD8+ TIS-T lymphocytes, Mo/Ma acquire some
effector response commonly attributed to the M2 phenotype.
These attributes include high production of angiogenic factors
such as IL-8, VEGF-A and MMP-9 together with low secretion
of IP-10. However, TIS-T lymphocytes promoted an uniform
increment of CD16 expression on the CD14+ Mo/Ma, and co-
expression of CD14 and CD16 is used to define a sub-
population of pro-inflammatory monocytes.31 This finding,
together with augmented production of NO, ROS and pro-
inflammatory cytokines by TIS-T cell-modulated Mo/Ma,
indicated that CD4+ or CD8+ TIS-T cells may also imprint
monocytes with attributes of inflammatory M1. Altogether, our
results demonstrate that the interaction between TIS-T cells
and monocytes results in the differentiation of a Mo/Ma
population with mixed M1 and M2 features.
Numerous reports link inflammation with tumorigenesis,
angiogenesis and metastasis.10 Based on that, it could be
speculated that, within the tumor microenvironment, TIS-T
cell/macrophage interaction may certainly have important
consequences for tumor progression since TIS-T cells
promote the production of mediators such as TNF, IL-1β
and IL-6. Particularly, TNF is a key cytokine involved in
inflammation, immunity, cellular homeostasis and tumor
progression.32 Regarding IL-6 and IL-1β, they are pleiotropic
cytokines with a broad range of functions that have been
shown to contribute to a microenvironment that promotes
angiogenesis and inflammation in cancer.10 The pro-
angiogenic function of inflammatory cytokines such as TNF
and IL-1β is mediated by the upregulation of angiogenic
factors such as VEGF, IL-8 and MMPs in vascular endothelial,
tumor and inflammatory cells.33 Indeed, considerable evi-
dence indicates that TAMs have an important role in regulating
angiogenesis within the tumor microenvironment as they
release a number of potent pro-angiogenic cytokines and
growth factors such as VEGF, TNF, IL-8 and bFGF, as well as
MMPs.34–36 In addition to inflammatory cytokines, Mo/Ma
modulated by TIS-T lymphocytes exhibit an increased
production of VEGF-A, IL-8 and MMP-9. Furthermore, we
observed that culture supernatants from Mo/Ma co-incubated
with CD4+ or CD8+ TIS-T lymphocytes have pro-angiogenic
effects as determined by their increased tubulogenesis and
tumor cell pro-survival potential. In spite of not identifying the
mediator/s, our results are in agreement with the findings that
pro-inflammatory cytokines and angiogenic factors provide
anti-apoptotic signals that prevent tumor cell death.37–39
Mo/Ma modulation mediated by TIS-T lymphocytes requires
cell-to-cell contact. Althoughwe cannot rule out the involvement
of additional pathways, we specifically demonstrated that Tim-
3/Gal-9 and CD40L/CD40 interactions participate in this
process. Interestingly, our results indicate that CD4+ and CD8+
TIS-T lymphocytes use different molecules to interact with Mo/
Ma and to regulate particular aspects such as secretion of pro-
inflammatory cytokines and angiogenic factors. The conse-
quences of Tim-3 signaling on T cells have been the focus of
numerous studies;40 however, recent reports established that
there is a reciprocal signal transmitted to the participating Gal-
9-expressing antigen presenting cell. Jayaraman et al.22
demonstrated that Tim-3 expressed on Th1 cells interacts
with its ligand Gal-9 expressed by Mycobacterium tubercu-
losis-infected macrophages to restrict intracellular bacterial
growth. Using an in vitro assay and in vivo model of
M. tuberculosis infection, these authors demonstrated that
Tim-3/Gal-9 interaction stimulates a significant production of
IL-1β, IL-6, TNF, MIP1αβ and G-CSF by infected macro-
phages. In addition, several studies reported the impact of
CD40L/CD40 interaction on macrophage response. Engage-
ment of CD40 on M1 macrophages induces the expression of
NO and TNF.41,42 In this context, demonstrating the participa-
tion of Tim-3/Gal-9 and CD40L/CD40 pathways on the
monocyte/macrophage modulation induced by TIS-T cells
may contribute to decipher the role of macrophages in human
tumors and may have therapeutic implications.
Treatment with anti-Tim-3 mAbs has been tested in vitro in
patients with melanoma and hepatocellular carcinoma as a
strategy to overcome T cell exhaustion and potentiate anti-
tumor immune response.3 In light of our results, we suggest
that the inhibition of Tim-3/Gal-9 pathway may affect the
effector function of different leukocyte subsets. Unraveling the
effects of anti-Tim-3 treatment on these several subsets will be
important for predicting the outcome of this approach in cancer
immunotherapy. Activation of CD40 pathways on macro-
phages may have a dual role in the survival and invasive
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capacity of tumor cells.43 However, several reports indicate
that CD40-activated macrophages produce inflammatory
mediators that promote chronic inflammation.44 In the same
direction, we observed that the CD40L/CD40 pathway is
involved in the enhancement of inflammatory activity of
macrophages induced by TIS-T cells.
In summary, our results provide evidence for a previously
uncharacterized role of TIS-T cells in humanMo/Mamodulation
that may impact on tumor progression. Considering that
macrophages are critical mediators of cancer-related inflam-
mation, focusing on this relationship between TIS-T cells and
macrophages may alter the balance of the type of tumor
inflammation and create opportunities for better anti-tumor
responses. Thus, future studies should be directed to better
understand macrophage functional changes induced by TIS-T
lymphocytes to best tailor the immune response against cancer.
Materials and Methods
Cell culture. Human peripheral blood mononuclear cells (PBMCs) from healthy
donors (age 25–40) were isolated by centrifugation over Ficoll-Hypaque gradients (GE
Healthcare Bio-Science AB, Uppsala, Sweden). CD4+ T cells, CD8+ T cells and
monocytes were purified by positive selection from total PBMCs using CD4, CD8 or
CD14 Microbeads (Miltenyi Biotech, San Diego, CA, USA) following manufacturer’s
instructions. The purity of each population was routinely checked and was 495% as
determined by flow cytometry. Ethical approval was obtained from the Hospital Nacional
de Clinicas Ethics Committee (16 October 2008). Purified CD4+ and CD8+ T cells and
monocytes were cultured with RPMI-1640 media supplemented with 10% fetal bovine
serum (Hyclone, Tauranga, New Zealand), 1% L-Glutamine (GlutaMax, Invitrogen Inc.,
Carlsbad, CA, USA) and 25 mmol/l Hepes (Cell Gro, Mediatech, Herndon, VA, USA).
Cell viability was routinely checked using a dye exclusion test while counting cells.
The human solid tumor cell line Tu167 and human HeLa cell lines were cultured in
RPMI-1640 and DMEM complete media, respectively, up to 90% confluence. HMEC-1
were grown in endothelial growth medium-2 (EGM-2, Lonza, Walkersville, MD, USA).
Induction of senescence by tumor cell line. TIS-T cells were obtained
as previously described.15 Briefly, CD4+ or CD8+ T lymphocytes were co-cultured
for 6 h with Tu167 cells at a 1 : 1 Tumor/T cell ratio. Then, the T cells were collected,
washed and cultured for 7 days in complete media. T cells collected after co-
incubation with tumor cells were found to be 99% CD3+ by flow cytometry. Purified
CD4+ or CD8+ T cells cultured for 7 days in complete media without a previous CC
with the tumor cell line were used as controls.
CCs and TW and blocking experiments. Monocytes and CD4+ or CD8+
TIS-T cells were co-cultured (1 : 1 ratio) in RPMI complete media for 40 h in the
presence of anti-CD3 mAb (TR66, in house preparation). As controls, monocytes were
cultured alone or co-cultured with CD4+ or CD8+ control-T cells (1 : 1 ratio). After
40 h, cultures were stimulated or not with LPS (50 ng/ml, InvivoGen E. coli 0111:B4)
for an extra 48 h. TW experiments were performed culturing monocytes in the lower
chamber and T cells were stimulated with anti-CD3/CD28/CD2 beads in the inserts
(0.4 μm pore size, Corning Life Sciences, Manassas, VA, USA). After the initial 40 h,
the cultures were stimulated with LPS as described. For blocking experiments,
monoclonal antibodies against Tim-3 (10 μg/ml, F38-2E2, Biolegend, San Diego, CA,
USA) and CD154 (10 μg/ml, 24–31, Biolegend) or isotype controls (10 μg/ml,
MOPC-21, Biolegend) were added at the beginning of the CC.
Flow cytometry. Mo/Ma were harvested and stained with anti-human CD14
AlexaFluor-647 or FITC, CD206 APC, Gal-9 PE, CD16 PE, CD40 PE-Cy5
(Biolegend), HLA-DR PE-Cy7, B7.H4 Biotin (eBioscience, San Diego, CA, USA) or
isotype controls in PBS with 2% FSB on ice for 20 min. T cells were harvested and
stained with mAb to human CD3 PerCP, CD27 APC-Alexa750, CD28 APC and
Tim-3 PerCP-eFluor710 (eBioscience).
To detect CD40L expression, PE-labeled anti-human CD40L/CD154 antibodies were
cultured with T cells in the presence of anti-CD3 mAb and Monensin solution
(eBioscience) during 40 h. Intracellular staining for phosphotyrosine was performed an
AlexaFluor-647-conjugated anti-human phosphotyrosine (PY20, Biolegend) antibody.
The production of ROS and NO was evaluated using the molecular probes: H2DCF-
DA (10 μM, Invitrogen Inc.) and DAF-FM DA (10 μM, Molecular Probes, Inc.),
respectively.
The assessment of phagocytosis was performed using 1 μm-Fluoresbrite Yellow
Green (YG) Carboxilate Microspheres (Polysciences, Inc., Warrington, PA, USA;
1 : 25 cell/microspheres ratio), which were added to CCs for 30 min. Afterwards, the
uptake of YG-microspheres was evaluated in CD14+ cells.
All samples were acquired on a FACS Canto II (BD Biosciences, San Jose, CA,
USA) and then analyzed with Flow Jo software (LLC, Ashland, OR, USA).
Quantification of cytokines, angiogenic and angiostatic factors.
Cytokines, angiogenic and angiostatic factors were measured in supernatant of
LPS-stimulated Mo/Ma co-cultured with CD4+ or CD8+ TIS-T or control-T cells.
TNF, IL-1β, IL-6 and IL-8 were measured by ELISA (Biolegend). VEGF-A, MMP-9
and IP-10 were measured by Flow Cytometry with Flow Cytomix Simplex kits
(eBioscience).
Western blot analysis. Monocytes and TIS-T and control-T cells were co-
cultured for 40 h as previously described, and then cultured with medium or LPS for
60 and 120 min. Then, using a protocol widely described by Wahl et al.,45 that takes
advantage of the ability of monocytes to adhere to plastic plates, T cells were
removed by repeatedly washing with warm PBS 1 × . Then, adherent Mo/Ma
(average purity 90%, routinely checked by flow cytometry) were lysed in 1 × SDS
reducing sample buffer. Extracts were sonicated for 15 s and immediately separated
on 10% SDS-PAGE gels, transferred to nitrocellulose membranes (BioRad Systems,
Hercules, CA, USA) and incubated with anti-phospho-IκBα (Ser32, 14D4), NF-κB2
p100/p52 (Cell Signaling Technology, Danvers, MA, USA) or p38 mAbs (loading
control, Sigma-Aldrich, St. Louis, MO, USA). Unstimulated Mo/Ma from CCs with
control-T or TIS-T cells were immunoblotted with antibodies against TLR-4 (Abcam,
Cambridge, MA, USA) and β-actin (Cell Signaling Technology). In all cases, protein
bands were detected by enhanced chemiluminescence (Thermo Scientific Pierce,
Rockford, IL, USA). The protein band intensities were analyzed using GelPro
Analyzer software (Media Cybernetics, Warrendale, PA, USA) and normalized to the
p38 or β-actin band.
Tumor-cell survival. HeLa cells were treated with Mitomycin C (75 μg/ml) for
30 min to inhibit cell proliferation. HeLa cells were cultured with supernatant of TIS-T
or control-T cell/Mo-Ma CCs or supernatants of Mo/Ma cultured alone during 48 h.
Then, we evaluated HeLa cell death/survival was then evaluated by flow cytometry
staining with 7- aminoactinomycin D (7-AAD from BD Pharmingen, San Diego, CA,
USA) during 15min.
In vitro tube formation assay. HMEC-1 cells were seeded at a density of
1.5 × 104 cells/well on plates coated with growth factor-reduced basement
membrane matrix (Matrigel, BD Biosciences) and cultured with supernatant of
TIS-T or control-T cell/Mo-Ma CCs or supernatants of Mo/Ma cultured alone. After
18 h, tube formation was examined by phase-contrast microscopy and the total
number of branch points was quantified by using ImageJ software (NIH, Bethesda,
MD, USA).
Cytospin and immunofluorescence microscopy. After 40 h, TIS-T or
control-T cell/Mo-Ma CCs were stimulated with LPS for 120 min, then T cells were
removed and Mo/Ma were centrifuged onto positively charged slides by cytospin,
fixed and permeabilized. After blockade, fixed cells were incubated with rabbit anti-
p65 antibodies (eBiosciences), AlexaFluor488-conjugated anti-rabbit IgG antibody
(Invitrogen Inc.) and propidium iodide (BD Biosciences) for nuclear staining. Finally,
stained slides were mounted with FluorSave (Calbiochem, Boston, MA, USA) and
analyzed by confocal microscopy (Olympus Fluoview 300, Olympus America Inc.,
Center Valley, PA, USA).
Statistical analysis. Statistical analysis was performed with GraphPad Prism
5.0 software (San Diego, CA, USA) by using One-way ANOVA and parametric or
non parametric paired t-test according to the data distribution. P-valueso0.05 were
considered significant.
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